Sana Biotechnology (SANA) Income towards Parent Company (2020 - 2026)

Sana Biotechnology has disclosed Income towards Parent Company across 7 years of filings, most recently posting -$47.7 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$47.7 million, up 3.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$244.5 million (down 19.73% YoY), and the FY2025 annual result was -$246.5 million, up 6.02% from the prior year.
• Income towards Parent Company came in at -$47.7 million for Q1 2026 at Sana Biotechnology, up from -$59.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $681000.0 in Q3 2023 to a low of -$113.9 million in Q2 2023.
• The 5-year median for Income towards Parent Company is -$59.9 million (2025), against an average of -$65.2 million.
• Across the five-year window, Income towards Parent Company jumped 100.8% in 2023 and sank 8790.46% in 2024, its largest moves.
• Sana Biotechnology's Income towards Parent Company stood at -$80.2 million in 2022, then decreased by 9.63% to -$87.9 million in 2023, then surged by 44.01% to -$49.2 million in 2024, then dropped by 21.77% to -$59.9 million in 2025, then increased by 20.46% to -$47.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$47.7 million (Q1 2026), -$59.9 million (Q4 2025), and -$42.5 million (Q3 2025), per Business Quant data.